Merck & Co., Inc. – NYSE:MRK

Add to watchlist

$84.93

-14.76

-14.81%

Market closed

Open in 1 day

-21.96%

month

-21.96%

quarter

-7.67%

year

Market Cap	249.29B
Enterprise value	275.74B

P/E	20.78
EV/Sales	4.36
EV/EBITDA	14.38
Price/Sales	3.98
Price/Book	5.67
PEG ratio	-1.70
EPS	0.91

Revenue	61.43B
EBITDA	8.71B
Income	2.30B
Revenue Q/Q	9.12%
Revenue Y/Y	6.16%

Profit margin	19.22%
Oper. margin	23.52%
Gross margin	74.97%
EBIT margin	23.52%
EBITDA margin	14.19%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Merck & Co. Stock Forecast

M Q Y

Last Year

$134

Potential upside: 57.77%

Analysts Price target
Financials & Ratios estimates

Merck & Co., Inc. (NYSE:MRK): Profit margin
Jun 2023	15.03B	-5.97B	-39.74%
Sep 2023	15.96B	4.74B	29.73%
Dec 2023	14.63B	-1.22B	-8.38%
Mar 2024	15.80B	4.76B	30.12%

Merck & Co., Inc. (NYSE:MRK): Payout ratio
Payout ratio	63.72%

Merck & Co., Inc. (NYSE:MRK): Dividend Yield
2019	2.56%
2020	3.15%
2021	3.41%
2022	2.5%
2023	2.62%

Merck & Co., Inc. (NYSE:MRK): Debt to assets
Jun 2023	104469000000	65.72B	62.92%
Sep 2023	106727000000	65.42B	61.3%
Dec 2023	106675000000	69.04B	64.72%
Mar 2024	105849000000	65.42B	61.81%

Merck & Co., Inc. (NYSE:MRK): Cash Flow
Jun 2023	3.70B	-11.44B	3.75B
Sep 2023	7.71B	-334M	-4.26B
Dec 2023	246M	53M	-2.24B
Mar 2024	3.09B	-1.37B	-2.81B

Merck & Co. alternative data

Merck & Co., Inc. (NYSE:MRK): Google Play Rank
Jul 2024	90

Merck & Co., Inc. (NYSE:MRK): Google Play Rank
Aug 2023	27
Sep 2023	43
Oct 2023	34
Nov 2023	38
Dec 2023	51
Jan 2024	37
Feb 2024	46
Mar 2024	61
Apr 2024	78
May 2024	95
Jun 2024	125
Jul 2024	89
Aug 2024	82
Sep 2024	92
Oct 2024	44
Nov 2024	40
Dec 2024	30

Merck & Co., Inc. (NYSE:MRK): Google Play Rank
Aug 2023	76
Sep 2023	96
Oct 2023	111
Nov 2023	92
Dec 2023	97
Jan 2024	131
Feb 2024	158
Mar 2024	126
Apr 2024	125
May 2024	135
Jun 2024	111
Jul 2024	104
Aug 2024	118
Sep 2024	107
Oct 2024	121
Nov 2024	184
Dec 2024	139

Merck & Co., Inc. (NYSE:MRK): App Store Rank
Aug 2023	471
Sep 2023	337
Oct 2023	409
Nov 2023	316
Dec 2023	224
Jan 2024	477
Feb 2024	263
Mar 2024	401
Jul 2024	412
Sep 2024	489
Oct 2024	378
Dec 2024	413

Merck & Co., Inc. (NYSE:MRK): App Store Rank
Aug 2023	35
Sep 2023	53
Oct 2023	41
Nov 2023	36
Dec 2023	44
Jan 2024	43
Feb 2024	40
Mar 2024	37
Apr 2024	72
May 2024	79
Jun 2024	82
Jul 2024	106
Aug 2024	88
Sep 2024	89
Oct 2024	90
Nov 2024	97
Dec 2024	105

Merck & Co., Inc. (NYSE:MRK): App Store Rank
Aug 2023	458

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Merck & Co. Social Media Accounts

Merck & Co., Inc. (NYSE:MRK): Followers count
May 2025	5293
Aug 2025	5359

Google Trends

Areas of Focus

Merck & Co., Inc. (NYSE:MRK): Google Trends - Areas of Focus
19 Feb 2023	15	2	2
26 Feb 2023	15	2	2
5 Mar 2023	15	2	2
12 Mar 2023	15	2	3
19 Mar 2023	15	2	2
26 Mar 2023	15	2	3
2 Apr 2023	13	2	3
9 Apr 2023	12	2	2
16 Apr 2023	13	2	3
23 Apr 2023	11	2	2
30 Apr 2023	10	2	2
7 May 2023	22	2	2
14 May 2023	26	2	2
21 May 2023	24	2	2
28 May 2023	33	2	2
4 Jun 2023	43	2	2
11 Jun 2023	51	2	2
18 Jun 2023	39	1	2
25 Jun 2023	52	1	2
2 Jul 2023	67	2	2

Merck

Merck & Co., Inc. (NYSE:MRK): Google Trends - Merck
19 Feb 2023	29
26 Feb 2023	29
5 Mar 2023	28
12 Mar 2023	31
19 Mar 2023	28
26 Mar 2023	29
2 Apr 2023	28
9 Apr 2023	34
16 Apr 2023	29
23 Apr 2023	29
30 Apr 2023	25
7 May 2023	30
14 May 2023	31
21 May 2023	28
28 May 2023	30
4 Jun 2023	31
11 Jun 2023	29
18 Jun 2023	22
25 Jun 2023	19
2 Jul 2023	29

MERCK and MSD Manual

Merck & Co., Inc. (NYSE:MRK): Google Trends - MERCK and MSD Manual
19 Feb 2023	53	28	3
26 Feb 2023	61	26	0
5 Mar 2023	60	20	0
12 Mar 2023	62	35	0
19 Mar 2023	58	33	2
26 Mar 2023	66	31	0
2 Apr 2023	65	35	0
9 Apr 2023	69	24	0
16 Apr 2023	56	28	3
23 Apr 2023	78	29	0
30 Apr 2023	55	21	2
7 May 2023	61	33	0
14 May 2023	51	31	0
21 May 2023	62	34	0
28 May 2023	54	21	0
4 Jun 2023	50	17	0
11 Jun 2023	55	21	2
18 Jun 2023	41	30	0
25 Jun 2023	50	22	0
2 Jul 2023	45	21	5

Numbers represent search interest relative to the highest point on the chart for the given region and time.

A value of 100 is the peak popularity for the term.
A value of 50 means that the term is half as popular.
A score of 0 means there was not enough data for this term.

Merck & Co., Inc. (NYSE:MRK): Job openings
Sep 2023	288
Oct 2023	446
Nov 2023	507
Jan 2025	213
Feb 2025	299
May 2025	226
Jul 2025	163
Aug 2025	167

Merck & Co.
Employees

Merck & Co., Inc. (NYSE:MRK): Employee count
Sep 2023	67,000
Oct 2023	67,000
Nov 2023	67,000
Dec 2023	67,000
Jan 2024	67,000
Feb 2024	67,000
Mar 2024	70,000
Apr 2024	70,000
May 2024	70,000
Jun 2024	70,000
Jul 2024	70,000

Merck & Co.
Hedge Funds Holdings Q1 2022

71.44% -1.23%

of MRK is owned by hedge funds

2.83K +19

hedge funds hold MRK stock

1.81B -29.73M

shares is hold by hedge funds

MRK hedge funds holdings changes

Merck & Co., Inc. (NYSE:MRK): Insider trades (number of shares)
Period	Buy	Sel
Apr 2023	0	343547
May 2023	0	117961
Aug 2023	0	8839
Nov 2023	0	45904
Feb 2024	0	409617

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	4 May 2024	SMART DALTON officer: SVP Fin. - Global Controller officer: SVP Fin. - Global Cont..	Common Stock	612	$127.51	$78,036
Option	4 May 2024	SMART DALTON officer: SVP Fin. - Global Controller officer: SVP Fin. - Global Cont..	Restricted Stock Unit	612	N/A	N/A
Option	4 May 2024	DELUCA RICHARD R. officer: EVP&Pres, Merck Animal Heallth officer: EVP&Pres, Merck Animal..	Common Stock	27,126	$127.51	$3,458,836
Option	4 May 2024	DELUCA RICHARD R. officer: EVP&Pres, Merck Animal Heallth officer: EVP&Pres, Merck Animal..	Restricted Stock Unit	27,126	N/A	N/A
Option	4 May 2024	KLOBUCHAR MICHAEL A officer: EVP - Chief Strategy Officer officer: EVP - Chief Strategy O..	Common Stock	887	$127.51	$113,101
Option	4 May 2024	KLOBUCHAR MICHAEL A officer: EVP - Chief Strategy Officer officer: EVP - Chief Strategy O..	Restricted Stock Unit	887	N/A	N/A
Option	4 May 2024	OOSTHUIZEN JOHANNES JACOBUS officer: President, U.S. Market officer: President, U.S. Market	Common Stock	912	$127.51	$116,289
Option	4 May 2024	OOSTHUIZEN JOHANNES JACOBUS officer: President, U.S. Market officer: President, U.S. Market	Restricted Stock Unit	912	N/A	N/A
Option	3 May 2024	SMART DALTON officer: SVP Fin. - Global Controller officer: SVP Fin. - Global Cont..	Common Stock	1,530	$128.26	$196,238
Option	3 May 2024	SMART DALTON officer: SVP Fin. - Global Controller officer: SVP Fin. - Global Cont..	Common Stock	516	$128.26	$66,182

Merck & Co.
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 25 Apr 2024	Q1 2024 Earnings Call Transcript
Q4 2023 1 Feb 2024	Q4 2023 Earnings Call Transcript
Q3 2023 26 Oct 2023	Q3 2023 Earnings Call Transcript
Q2 2023 1 Aug 2023	Q2 2023 Earnings Call Transcript

MRK earnings call transcripts

Merck & Co.
Executives

Insider	Age	Compensation
Mr. Kenneth C. Frazier (1955) Executive Chairman	70	$4,300,000
Mr. Robert M. Davis (1967) Pres, Chief Executive Officer & Director	58	$2,290,000
Ms. Jennifer L. Zachary (1978) Executive Vice President, Gen. Counsel & Corporation Sec.	47	$1,790,000
Mr. Sanat Chattopadhyay (1960) Executive Vice President & Pres of Merck Manufacturing Division	65	$1,560,000

Merck & Co.
Latest News

Thursday, 26 December 2024
09:45	2 Reasons to Sell Merck Stock and 1 Reason to Buy	fool.com
Tuesday, 24 December 2024
18:51	Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing	zacks.com
Monday, 23 December 2024
18:43	Merck to discontinue drug for bacterial infection	reuters.com
09:00	Merck: A Low-Hanging Fruit To Pick	seekingalpha.com
Sunday, 22 December 2024
14:51	Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More	benzinga.com
06:45	Is Merck the Next Big Weight-Loss Stock?	fool.com
Friday, 20 December 2024
14:05	Stocks on the Move: Uber, Carmax, Novo Nordisk, Eli Lilly, Merck, Crown Castle and Accenture	youtube.com
10:21	MRK's Pivotal Study on Two-Drug, Once-Daily HIV Pill Meets Goals	zacks.com
10:06	Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know	zacks.com
07:45	Want to Collect a Dividend Every Month? Invest in These 3 High-Yielding Income Stocks	fool.com
06:45	Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody	businesswire.com
Thursday, 19 December 2024
11:54	Stock Of The Day: Where Does The Merck Downtrend End?	benzinga.com
09:26	Merck Enters Obesity Space, Buys Rights to Hansoh's Oral GLP-1 Drug	zacks.com
08:46	Dow Losing Streak Longest in 50 Years: Grab These Bargain Blue-Chip Dividend Stocks Now	247wallst.com
08:32	Merck: Healthcare Pharma Giant: 3.2% Yield, 9.3% 5-Year Dividend Growth, Buy Time	seekingalpha.com
06:59	Merck's HIV treatment meets main goal of two late-stage studies	reuters.com
06:45	Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection	businesswire.com
Wednesday, 18 December 2024
12:02	Merck's weight-loss pill deal: what it means for Eli Lilly	invezz.com
11:28	Merck pens $2bn deal for obesity drug from China's Hansoh	proactiveinvestors.com
11:00	Merck's BLA for RSV Antibody Clesrovimab Gets FDA Acceptance	zacks.com
10:51	Merck to End Development of Two Cancer Candidates: Time to Sell?	zacks.com
10:25	Merck Licenses a Weight-Loss Pill. It's Bad News for Obesity Biotechs.	barrons.com
07:59	Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal	cnbc.com
06:59	Merck signs up to $2 bln obesity drug deal with Chinese biotech Hansoh	reuters.com
06:45	Merck Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist	businesswire.com
Tuesday, 17 December 2024
13:40	Barclays fact-checked Trump comments on pharmacy benefit managers	https://thefly.com
10:05	Merck Ends Development of Two Experimental Cancer Drugs	zacks.com
06:45	Merck Announces FDA Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants from RSV Disease During their First RSV Season	businesswire.com
05:24	Merck: Buy Opportunity Backed By Growth	seekingalpha.com
Monday, 16 December 2024
16:38	Merck discontinues development of 2 cancer drugs after trial failures	reuters.com

Ideas & Opinions

Seeking Alpha 18 Aug 2025

Merck: Shares Bucking The Gardasil Problem, Hiking My Price Target
Seeking Alpha 16 Aug 2025

Merck: Buy The Weakness
Seeking Alpha 12 Aug 2025

Tesla's Stock Should Be 10 Times Cheaper (Rating Downgrade)
Seeking Alpha 11 Aug 2025

Industry Analysis: Pharmaceuticals Like Novo Nordisk Offer Long-Term Opportunities
Seeking Alpha 6 Aug 2025

Stock Picks From Seeking Alpha's July 2025 New Analysts
Seeking Alpha 29 Jul 2025

Merck Stock Is Almost A Classical Benjamin Graham Investment
Seeking Alpha 28 Jul 2025

GSK: I Foresee Only Very Modest Upside Here Even If Blenrep Gets FDA Approval
Seeking Alpha 23 Jul 2025

Pfizer: Building The Next Oncology Empire
Seeking Alpha 18 Jul 2025

Zoetis: Poised For Growth Yet Priced For Decline (Rating Upgrade To Strong Buy)
Seeking Alpha 17 Jul 2025

Takeda: Positioned To Tackle Future Clinical Demand In A Highly Regulated Sector

Frequently Asked Questions (FAQ)

What's the price of Merck & Co. stock today?

One share of Merck & Co. stock can currently be purchased for approximately $84.93.
When is Merck & Co.'s next earnings date?

Unfortunately, Merck & Co.'s (MRK) next earnings date is currently unknown.
Does Merck & Co. pay dividends?

Yes, Merck & Co. pays dividends and its trailing 12-month yield is 3.13% with 64% payout ratio. The last Merck & Co. stock dividend of $0.69 was paid on 7 Jan 2022.
How much money does Merck & Co. make?

Merck & Co. has a market capitalization of 249.29B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 1.4% to 60.12B US dollars.
What is Merck & Co.'s stock symbol?

Merck & Co., Inc. is traded on the NYSE under the ticker symbol "MRK".
What is Merck & Co.'s primary industry?

Company operates in the Healthcare sector and Drug Manufacturers - General industry.
How do i buy shares of Merck & Co.?

Shares of Merck & Co. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Merck & Co.'s key executives?
Merck & Co.'s management team includes the following people:
- Mr. Kenneth C. Frazier Executive Chairman(age: 70, pay: $4,300,000)
- Mr. Robert M. Davis Pres, Chief Executive Officer & Director(age: 58, pay: $2,290,000)
- Ms. Jennifer L. Zachary Executive Vice President, Gen. Counsel & Corporation Sec.(age: 47, pay: $1,790,000)
- Mr. Sanat Chattopadhyay Executive Vice President & Pres of Merck Manufacturing Division(age: 65, pay: $1,560,000)
How many employees does Merck & Co. have?

As Jul 2024, Merck & Co. employs 70,000 workers.
When Merck & Co. went public?

Merck & Co., Inc. is publicly traded company for more then 47 years since IPO on 13 Jan 1978.
What is Merck & Co.'s official website?

The official website for Merck & Co. is merck.com.
Where are Merck & Co.'s headquarters?

Merck & Co. is headquartered at 2000 Galloping Hill Road, Kenilworth, NJ.
How can i contact Merck & Co.?

Merck & Co.'s mailing address is 2000 Galloping Hill Road, Kenilworth, NJ and company can be reached via phone at +90 87404000.
What is Merck & Co. stock forecast & price target?

Based on 5 Wall Street analysts` predicted price targets for Merck & Co. in the last 12 months, the avarage price target is $134. The average price target represents a 57.77% change from the last price of $84.93.

Merck & Co., Inc.

merck.com

Exchange:

NYSE

Full time employees:

70,000

Industry:

Drug Manufacturers - General

Sector:

Healthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

+90 87404000

2000 Galloping Hill Road
Kenilworth, NJ 07033

CIK: 0000310158
ISIN: US58933Y1055
CUSIP: 58933Y105